Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C

Дата публикации: 23-07-2026 21:07:44

INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Boehringer Ingelheim Strengthens Obesity Pipeline as Potential First-in-Class Triple Receptor Agonist BI 3034701 Enters Phase II Development	0	13.34	16-07-2026
2	Eli Lilly alza le stime 2026, boom di Mounjaro e Zepbound	0	12.54	05-08-2026
3	Novo Nordisk porta Eli Lilly in tribunale: si accende la sfida sui farmaci anti-obesità	0	10.48	22-07-2026
4	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
5	'Godzilla' weight-loss shot that's more powerful than Ozempic set to be offered to some patients ahead of FDA approval: Find out if you're eligible	0	9.55	04-08-2026
6	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
7	Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer	0	9.33	03-08-2026
8	Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer.	0	18.59	12-08-2026
9	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	0	12.36	14-06-2026
10	FDA orders Eli Lilly and Novo Nordisk to remove suicide warnings from Wegovy and Zepbound	0	7.76	15-01-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.62. Источник: www.drugs.com.